In the life science field, natural antibodies stand as formidable protectors of organisms. However, while these antibodies provide a strong immune defense, they may fall short in meeting the demands of modern medicine and scientific research. This is where recombinant engineered antibodies come in – a groundbreaking advancement that ushers in a new era of enhanced therapeutic potential.

Through the process of genetic engineering, antibody genes are designed with precision, modified, and recombined to create a new class of antibodies with unique properties and capabilities. These cutting-edge antibodies offer unparalleled specificity and affinity, targeting a wide range of complex diseases with unparalleled precision. From revolutionizing cancer immunotherapy to treating autoimmune conditions, the potential of recombinant antibodies is limitless in their ability to provide effective and tailored treatment options.

Recombinant Antibody Preparation Process

  • Hybridoma Sequencing: By sequencing monoclonal antibodies against hybridoma cells, the full-length sequence information of the antibody is obtained. The heavy and light chains of the antibody can then be further analyzed comprehensively.

  • Plasmid Construction and Transfection: By sequencing monoclonal antibodies against hybridoma cells, the full-length sequence information of the antibody is obtained. The heavy and light chains of the antibody can then be further analyzed comprehensively.

  • Antibody Expression, Purification, and Characterization: Select appropriate expression conditions and cell lines for antibody expression. Purification and characterization are key steps in quality control.

  • Expansion Cultivation: Through stable cell strain screening, expansion cultivation and further purification of antibodies are achieved.

Flowchart of Recombinant Antibody Preparation

Recombinant Antibodies VS Natural Antibodies

Recombinant antibodies include chimeric antibodies, humanized antibodies, small molecule antibodies, and bispecific antibodies. They are currently widely used in scientific research, immunodiagnosis and therapeutic antibody fields. Compared with traditional antibodies, recombinant antibodies have many advantages.

  1. No Animal Components
    Recombinant antibodies are produced in a cell culture, and are therefore completely free of animal components. This virtually eliminates human immune rejection caused by animal-derived antibodies.
  2. Antibody Modification
    Modification of existing mouse monoclonal antibodies genetically improves the specificity and sensitivity of the antibody. The modified antibodies are also highly humanized, which provides a more efficient tool for disease treatment and diagnosis.
  3. High Batch-to-Batch Consistency
    Compared to natural antibodies, recombinant antibodies with fixed sequences significantly improve batch-to-batch consistency and stability.
  4. Large-scale Production
    The production of natural antibodies often fails to meet large-scale demand. Recombinant antibodies are produced via E. coli or mammalian cells, allowing for direct large-scale production and shorter production cycles.

Recombinant antibodies, with their own advantages, are widely used in basic research and drug development for various diseases. In the future, with the increasing demand for antibody humanization, the application of recombinant antibodies will continue to broaden even further.

Your Recombinant Antibodies Partner

Synbio Technologies is committed to producing high quality recombinant antibodies. We provide comprehensive, one-stop services for the production of engineered antibodies. This includes gene synthesis, transfection plasmid preparation, and recombinant antibody production. Discover the limitless potential of recombinant antibodies for yourself at Synbio Technologies!


  1. Pan X, Kortemme T. Recent advances in de novo protein design: Principles, methods, and applications. J Biol Chem. 2021 Jan-Jun;296:100558.
  2. Basu K, Green E M, Cheng Y, et al. Why recombinant antibodies—benefits and applications[J]. Current opinion in biotechnology, 2019, 60: 153-158.
  3. Pollet J, Chen W H, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics[J]. Advanced drug delivery reviews, 2021, 170: 71-82.
  4. Kang T H, Seong B L. Solubility, stability, and avidity of recombinant antibody fragments expressed in microorganisms[J]. Frontiers in Microbiology, 2020, 11: 1927.
  5. Marx V. Change-makers bring on recombinant antibodies[J]. Nature Methods, 2020, 17(8): 763-766.
  6. Corti D, Kearns J D. Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease[J]. Current Opinion in Immunology, 2016, 40: 51-61.